UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from
dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor
cells.
PURPOSE: This phase I trial is studying the side effects and best dose of fludarabine when
given with UCN-01 in treating patients with recurrent or refractory low-grade lymphoma or
leukemia.